Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
BioSHaRE Resource Report Resource Website 10+ mentions |
BioSHaRE (RRID:SCR_003811) | BIOSHARE-EU | consortium, data or information resource, narrative resource, organization portal, portal, standard specification | A consortium of leading biobanks and international researchers from all domains of biobanking science to ensure the development of harmonized measures and standardized computing infrastructures enabling the effective pooling of data and key measures of life-style, social circumstances and environment, as well as critical sub-components of the phenotypes associated with common complex diseases. The overall aim is to build upon tools and methods available to achieve solutions for researchers to use pooled data from different cohort and biobank studies. This, in order to obtain the very large sample sizes needed to investigate current questions in multifactorial diseases, notably on gene-environment interactions. This aim will be achieved through the development of harmonization and standardization tools, implementation of these tools and demonstration of their applicability. BioSHaRE researchers are collaborating with P3G, the Global Alliance for Genomics and Health, IRDiRC (International Rare Diseases Research Consortium), H3Africa and other organizations on the development of an International Code of Conduct for Genomic and Health-Related Data Sharing. A draft version is available for external review. Generic documents have been prepared covering areas of biobanking that are of major importance. SOPs have been finalized for blood withdrawal (SOPWP5001blood withdrawal), manual blood processing (SOPWP5002blood processing), shipping of biosamples (SOPWP5003shipping) and withdrawal, processing and storage of urine samples (SOPWP5004urine). | gene-environment interaction, life-style, social circumstance, environment, phenotype, disease, biobank, socio-economic factor, data sharing, gene, clinical |
is listed by: Consortia-pedia has parent organization: University of Groningen; Groningen; Netherlands is parent organization of: BioResource Impact Factor |
European Union FP7 | nlx_158110 | SCR_003811 | Biobank Standardisation and Harmonisation for Research Excellence, Biobank Standardisation and Harmonisation for Research Excellence in the European Union | 2026-09-03 04:46:46 | 22 | |||||||
|
Canadian Consortium on Neurodegeneration in Aging Resource Report Resource Website |
Canadian Consortium on Neurodegeneration in Aging (RRID:SCR_003846) | CCNA | consortium, data or information resource, organization portal, portal | Consortium that will be the premier research hub for all aspects of research involving neurodegenerative diseases that affect cognition in aging - including Alzheimer's disease. They will promote high impact, inter-institutional and interdisciplinary collaboration through a pan-Canadian approach, and will position Canadian researchers to lead and participate in a new wave of national and international initiatives with congruent goals. The consortium focuses research into the basic mechanisms of neurodegenerative diseases, accelerating the development of tools that can be used to assist in the diagnosis and treatment of the diseases. The intended outcome of these tools is to improve the quality of life and services patients with neurodegenerative diseases. As part of the Canadian contribution to the International Collaborative Research Strategy for Alzheimer's disease, the consortium brings together Canadian government agencies (federal and provincial), foundations, pharmaceutical companies, philanthropists and international stakeholders to identify if there are common causes and risk factors to neurodegenerative diseases. The consortium is focused on three themes: * Primary Prevention aimed at preventing the disease from developing * Secondary Prevention focused on delaying the clinical manifestations of the already developing disease * Quality of Life designed for helping individuals, caregivers and the health system in the context of a clinically developed disease. | cognition, biomarker, primary prevention, secondary prevention, quality of life, clinical, late adult human, prevention |
is listed by: Consortia-pedia has parent organization: Institute of Aging - CIHR |
Canadian Institutes of Health Research ; Alzheimer Society of Canada ; Alzheimers Research UK |
nlx_158160 | SCR_003846 | Canadian Consortium on Neurodegeneration in Aging (CCNA) | 2026-09-03 04:46:37 | 0 | |||||||
|
BiomarCaRE Resource Report Resource Website 10+ mentions |
BiomarCaRE (RRID:SCR_003841) | BIOMARCARE, BiomarCaRE | consortium, data or information resource, organization portal, portal | EU funded consortium including over 30 partner from academia and industry. BiomarCaRE aims to determine the value of established and emerging biomarkers to improve risk estimation of cardiovascular disease in Europe. BiomarCaRE relies on an exceptional resource of large scale epidemiological cohorts with long term follow-up and available bio specimens based on the population of the MORGAM Project as well as several cardiovascular disease cohorts and clinical trials. | drug, biomarker, diagnostic, cardiovascular risk, phenotype, ultrasound, mri, clinical, epidemiological, risk prediction, lifestyle, risk factor, heart | is listed by: Consortia-pedia | European Union FP7 | nlx_158154, SCR_013677 | SCR_003841 | BiomarCaRE.EU, Biomarker for Cardiovascular Risk Assessment in Europe (BIOMARCARE), Biomarker for Cardiovascular Risk Assessment in Europe | 2026-09-03 04:46:41 | 28 | |||||||
|
Nephrology Nursing Certification Commission Resource Report Resource Website |
Nephrology Nursing Certification Commission (RRID:SCR_003994) | NNCC | data or information resource, organization portal, portal, training resource | Organization that established credentialing mechanisms to promote patient safety and to improve the quality of care provided to nephrology patients. There is a diversity of examinations providing the opportunity for certification at various levels of education, experience, and areas of practice within nephrology nursing. All of the certification examinations are endorsed by American Nephrology Nurses'''' Association (ANNA). The Commission recognizes the value of education, administration, research, and clinical practice in fostering personal and professional growth and currently provides six examinations to validate clinical performance: * The Certified Dialysis Nurse examination * The Certified Dialysis LPN/LVN examination * The Certified Nephrology Nurse examination * The Certified Clinical Hemodialysis Technician * The Certified Clinical Hemodialysis Technician - Advanced * The Certified Nephrology Nurse - Nurse Practitioner | nephrology, kidney, nursing, certification, clinical, dialysis, hemodialysis |
is related to: American Nephrology Nurses Association is related to: Kidney Health Initiative |
Kidney disease | nlx_158407 | SCR_003994 | Nephrology Nursing Certification Board, NNCB | 2026-09-03 04:46:51 | 0 | |||||||
|
Comprehensive Biomarker Center Resource Report Resource Website |
Comprehensive Biomarker Center (RRID:SCR_003901) | CBC | commercial organization | Commercial organization that discovers, validates & analyzes genomic biomarkers with a focus on body fluid samples. Take advantage of their proven expertise in biomarker signature development and speed up your biomarker studies. | biomarker, clinical research organization, genomic biomarker, genomic, diagnostic, testing, bodily fluid, clinical, dna, rna, dna extraction, rna extraction, microarray, next-generation sequencing, validation, microrna | is related to: READNA | nlx_158236 | SCR_003901 | febit, febit GmbH, Comprehensive Biomarker Center Gmbh | 2026-09-03 04:46:52 | 0 | ||||||||
|
Hospira Resource Report Resource Website 100+ mentions |
Hospira (RRID:SCR_003985) | Hospira | commercial organization | American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois.Provider of injectable drugs and infusion technologies and global leader in biosimilars. From September 2015 Hospira is part of Pfizer. | drug, infusion pump, software, device, contract manufacturing, clinical, intravenous set |
is related to: Kidney Health Initiative is related to: Pfizer Inc. |
nlx_158395 | SCR_003985 | Hospira Inc., | 2026-09-03 04:46:50 | 122 | ||||||||
|
ERA-EDTA Resource Report Resource Website 10+ mentions |
ERA-EDTA (RRID:SCR_003982) | ERA-EDTA | community building portal, data or information resource, portal | An association of European kidney specialists whose objective is advancement of medical science and of clinical work in nephrology, dialysis, renal transplantation, hypertension and related subjects. They aim at providing up-to-date knowledge, exclusively based on scientific data, independent from governments'' policies and from any influence of the industry. It is registered in England and Wales, but its area of activity mainly covers Europe and the Mediterranean area. | kidney, dialysis, transplant, nephrology, medical, clinical, renal transplantation, hypertension | is related to: Kidney Health Initiative | Kidney disease | nlx_158389 | SCR_003982 | European Renal Association - European Dialysis and Transplant Association, European Renal Association - European Dialysis & Transplant Association | 2026-09-03 04:46:51 | 22 | |||||||
|
Quartz Bio Resource Report Resource Website |
Quartz Bio (RRID:SCR_003919) | QBIO | commercial organization | A Swiss service and consulting company specialized in the computational analysis of biomarker data from clinical trials. Their technical expertise spans across multiple biomaker technological platforms such as genetics, transcriptomics, protein assays and cellular assays. Quartz Bio is a spin-off of Merck Serono with the capital of the company entirely owned by its employees. | clinical, bioinformatics, medicine, biomarker, clinical trial, data analysis | is related to: PRECISESADS | nlx_158280 | SCR_003919 | Quartz Bio S.A. | 2026-09-03 04:46:38 | 0 | ||||||||
|
Qualissima Resource Report Resource Website |
Qualissima (RRID:SCR_003941) | Qualissima | commercial organization | A Research as a Service (RaaS) Company founded by a Clinical Pharmacologist and Neuropsychiatrist that offers to its partners (health products industries and public research), 3 platforms: * Clinical research (CRO and SMO) * Scientific & regulatory consulting * Online surveys (Web portal) Their Research & Development profile allows them to propose innovative concepts such as : * Patient-Leader studies * Translational research studies (fMRI, innovative biomarkers, modeling, ...) * Behavioral parameters as biomarkers studies Qualissima also proposes proof of concept studies, proof of activities studies, medical devices studies and observational studies. | neurodegeneration, central nervous system, cardiology, dermatology, infectiology, cancerology, biomarker, clinical trial, clinical | is related to: PharmaCog | grid.492092.4, nlx_158328 | https://ror.org/008zpgd78 | SCR_003941 | Qualissima GmbH | 2026-09-03 04:46:47 | 0 | |||||||
|
Arbor Research Collaborative for Health Resource Report Resource Website 1+ mentions |
Arbor Research Collaborative for Health (RRID:SCR_003972) | Arbor Research | nonprofit organization | A not-for-profit research organization committed to improve patient care through research that shapes medical policies and practice. In particular, they conduct health outcomes research on chronic disease and end-stage organ failure, with expertise in biostatistical analysis, clinical practice, health economics, public policy, database management and integration, and project coordination. Through research projects that are national and global in scope, their scientific collaborations provide valuable and timely information to the worldwide health care community. They are a leader in interdisciplinary health outcomes and policy research focused on reducing the health and economic burden of chronic diseases and improving the delivery of care. | health outcome, patient care, clinical, policy, nephrology, statistics, kidney, transplant, dialysis, epidemiology, public health, clinical practice, policy development, medical payment system | is related to: Kidney Health Initiative | Kidney disease, Organ failure, Chronic disease | grid.413857.c, nlx_158379, ISNI: 0000 0004 0628 9837 | https://ror.org/043qmbk61 | SCR_003972 | URREA, University Renal Research and Education Association | 2026-09-03 04:46:50 | 3 | ||||||
|
American Nephrology Nurses Association Resource Report Resource Website 1+ mentions |
American Nephrology Nurses Association (RRID:SCR_003966) | ANNA | institution | Non-profit professional association that represents nurses who work in all areas of nephrology including hemodialysis, chronic kidney disease, peritoneal dialysis, acute care, and transplantation. Most members work in freestanding dialysis units, hospital outpatient units, and hospital inpatient units. ANNA develops and updates standards of clinical practice, educates practitioners, stimulates and supports research, disseminates knowledge and new ideas, promotes interdisciplinary communication and cooperation, and monitors and addresses issues encompassing the breadth of practice of nephrology nursing. | clinical, kidney, nephrology, nurse, health care, dialysis, journal, training resource |
is related to: Nephrology Nursing Certification Commission is related to: Kidney Health Initiative |
Kidney disease | grid.469735.a, nlx_158371, ISNI: 0000 0000 9310 7210, Crossref funder ID: 100005526 | https://ror.org/05a8c4g41 | SCR_003966 | American Nephrology Nurses'' Association | 2026-09-03 04:46:49 | 1 | ||||||
|
Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis - Unresponsive Populations Resource Report Resource Website |
Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis - Unresponsive Populations (RRID:SCR_004019) | BATTER-UP | data or information resource, portal, topical portal | A consortium evaluating a new biomarker screening test that might help identify patients with rheumatoid arthritis (RA) who are unlikely to benefit from anti-tumor necrosis factor-alpha (TNFalpha) medications. BATTER-UP will enroll around 1,000 patients being treated by one of several marketed anti-TNF RA drugs: Enbrel, Remicade, Humira, Simponi, or Cimzia. Through data analyses and predictive response modeling, the consortium aims to better understand which patients with RA will derive the greatest benefit from TNF inhibitors. The investigators in this observational study will attempt to validate an 8-gene biomarker set based on work by Biogen Idec researchers as likely to predict anti-TNF responsiveness in patients with RA. In preliminary results, the 8-gene biomarker set predicted with 89% accuracy individuals who did not reach European League Against Rheumatism (EULAR) Disease Activity Score (DAS)-28 good response after 14 weeks of treatment. The 8 genes included in the screen are CLTB, MXRA7, CXorf52, COL4A3BP, YIPF6, FAM44A, SFRS2, and PGK1. Biological samples and clinical outcome information will be used to confirm and extend the utility of previously published biomarkers that can predict response to anti-TNF agents. These data may also generate new hypotheses for further testing. The BATTER-UP samples and data will be established as a reference set for investigation of personalized medicine in RA. The study will be a resource of DNA and other biological materials that can be investigated for biomarkers in the future as new technologies arise. | anti-tumor necrosis factor-alpha, gene, biomarker, drug development, basic research, personalized medicine, enbrel, remicade, humira, simponi, cimzia, cltb, mxra7, cxorf52, col4a3bp, yipf6, fam44a, sfrs2, pgk1, clinical, dna, serum, plasma, rna, whole blood |
uses: ClinicalTrials.gov is listed by: Consortia-pedia is related to: Feinstein Institute for Medical Research has parent organization: Feinstein Institute for Medical Research has parent organization: ClinicalTrials.gov |
Biogen Idec ; Bristol-Myers Squibb ; Centocor ; Crescendo Bioscience ; Genentech ; Medco Health Solutions ; Regeneron Pharmaceuticals ; Sanofi-Aventis |
nlx_158440 | SCR_004019 | Biomarkers of Anti-TNF-alpha Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients, Biomarkers of Anti-TNF- Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients (BATTER-UP), Biomarkers of Anti-TNF- Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients | 2026-09-03 04:46:48 | 0 | |||||||
|
Genomedics Resource Report Resource Website |
Genomedics (RRID:SCR_004103) | Genomedics | commercial organization | A commercial company specialized in the field of clinical governance, research and clinical-epidemiological analysis and development of services and software applications for healthcare. Products and Services * Analysis and development software solutions, web, e-learning * Design and Implementation APP for Smartphone and Tablet (iOS, Android, Windows Phone) * Clinical Intelligence & Clinical Decision Support Systems (CDSS) * Data center services and Application Server Provider * Epidemiology, Surveillance and Health Promotion - Development of studies and epidemiological research | healthcare, clinical, medicine, health, information service, analysis, software development, web portal, multimedia, e-learning, data center service, application server, business intelligence, epidemiology, surveillance, health promotion, population | is related to: EMIF | nlx_158578 | SCR_004103 | Genomedics health care consultants, Genomedics S.r.l. | 2026-09-03 04:46:58 | 0 | ||||||||
|
Vascular Access Society of the Americas Resource Report Resource Website |
Vascular Access Society of the Americas (RRID:SCR_004058) | VASA | community building portal, data or information resource, portal | Society devoted to the advancement of the field of dialysis access through research, education and advocacy for patients with end stage kidney disease. They provide vascular access education for physicians, nurses, and other health care professionals and advocate for evidenced-based best clinical practices. | dialysis, kidney, clinical, vascular | is related to: Kidney Health Initiative | End stage kidney disease | nlx_158492 | SCR_004058 | 2026-09-03 04:46:55 | 0 | ||||||||
|
Vasculitis Foundation Resource Report Resource Website |
Vasculitis Foundation (RRID:SCR_004059) | VF | institution | An international organization for patients with vasculitis, their families, friends and the health care professionals who care for them, supporting and empowering them through education, awareness and research. The Foundation advocates for early diagnosis and leading edge treatment for all. The Foundation also partners with researchers around the world to determine the cause and discover the cure for vasculitis. | clinical, pediatric, child, funding resource | is related to: Kidney Health Initiative | Vasculitis | Crossref funder ID: 100007211, grid.453926.f, nlx_158493 | https://ror.org/03f9wqe45 | SCR_004059 | 2026-09-03 04:46:52 | 0 | |||||||
|
Thrasos Therapeutics Resource Report Resource Website |
Thrasos Therapeutics (RRID:SCR_004052) | Thrasos | commercial organization | Private, clinical stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. They are committed to developing novel approaches to protect, treat and restore kidney function for this patient group. Company has designed specific class of peptide compounds that have shown excellent results in controlling experimental kidney diseases, notably, models of diabetic nephropathy (kidney damage associated with diabetes), and acute kidney injury. These proprietary peptides may therefore be able to prevent and treat acute kidney injury, as well as slow and possibly reverse the progression of diabetic nephropathy. They act to control apoptosis (programmed cell death), inflammation and fibrosis (formation of scar tissue). | Controlling experimental kidney diseases, biotherapeutics, clinical, peptide, treat acute kidney injury, reverse progression diabetic nephropathy | is related to: Kidney Health Initiative | Kidney disease, Acute kidney injury, Diabetic nephropathy, Chronic kidney disease | nlx_158489 | http://www.thrasos.com/ | SCR_004052 | Thrasos Innovation Inc. | 2026-09-03 04:46:51 | 0 | ||||||
|
MPS Hamburg Resource Report Resource Website 1+ mentions |
MPS Hamburg (RRID:SCR_004087) | MPS | commercial organization | Full service Clinical Research Organization (CRO) in Hamburg, Germany, mainly focusing on phase-I and phase-IIa clinical trials. MPS owns 72 bed research clinic with 6 physicians and 15 nurses as permanent staff. MPS is experienced in performing all kind of early stage clinical trials, including first-in-man-trials, medical-devices-trials, nutraceutical and consumer-goods-trials. MPS holds active database of more than 17,000 healthy volunteers, plus hundreds of patients in special populations. | clinical trial, clinical, medical device, patient registry, healthy, nutraceutical, consumer-goods, pharmaceutical | is related to: European Gram Negative AntiBacterial Engine | nlx_158544 | SCR_004087 | MPS Hamburg GmbH | 2026-09-03 04:46:54 | 1 | ||||||||
|
Big Ten Cancer Research Consortium Resource Report Resource Website |
Big Ten Cancer Research Consortium (RRID:SCR_004025) | BTCRC | consortium, data or information resource, organization portal, portal | A consortium that aims to transform cancer research through collaborative oncology trials that leverage the scientific and clinical expertise of the Big Ten universities. The goal is to align the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise. The clinical trials that will be developed will be linked to molecular diagnostics, enabling researchers to understand what drives the cancers to grow and what might be done to stop them from growing. The consortium also leverages geographical locations and existing relationships among the cancer centers. One of the consortium's goals is to harmonize contracts and scientific review processes to expedite clinical trials. The consortium will only focus on phase 0 to II trials because larger trials - even a randomized phase II trial - are difficult to conduct at a single cancer center. | oncology, drug development, basic research, clinical trial, clinical, genitourinary, gastrointestinal, thoracic, breast, nanotechnology, virus, triple-negative cell |
is affiliated with: Penn State Milton S. Hershey Medical Center; Pennsylvania; USA is affiliated with: University of Wisconsin-Madison; Wisconsin; USA is affiliated with: Rutgers University; New Jersey; USA is affiliated with: Northwestern University; Illinois; USA is affiliated with: University of Nebraska; Nebraska; USA is affiliated with: University of Minnesota Twin Cities; Minnesota; USA is affiliated with: Michigan State University; Michigan; USA is affiliated with: University of Michigan; Ann Arbor; USA is affiliated with: University of Iowa; Iowa; USA is affiliated with: Indiana University; Indiana; USA is affiliated with: University of Illinois College of Medicine; Illinois; USA has parent organization: Hoosier Cancer Research Network |
Cancer | Public | nlx_158452 | SCR_004025 | Big Ten CRC | 2026-09-03 04:46:49 | 0 | ||||||
|
EU-ADR Resource Report Resource Website 1+ mentions |
EU-ADR (RRID:SCR_004028) | EU-ADR | consortium, data or information resource, organization portal, portal | Consortium that created the capability to detect Adverse Drug Response (ADR) signals by creating the infrastructure for large-scale monitoring of drug safety using electronic health records (EHR). The platform leverages EHR''''s comprising demographics, drug use and clinical data of over 30 million patients from several European countries. Special attention was given to patient groups that are not routinely involved in clinical trials, for ethical or practical reasons (e.g. pregnant women, elderly people, people using many drugs simultaneously, and children). This project also studies and compares a number of different techniques that all aim to detect unexpected or disproportional rates of events. The algorithms that they studied originate not only from the field of (pharmaco)epidemiology, but also from fields such as bio-terrorism, machine learning, and classical signal detection. EU-ADR specific objectives are: To detect events, To relate these events to drugs, To develop hypothesis that explain adverse events, To detect adverse events earlier, and To avoid false positives. The web-based platform is available at https://bioinformatics.ua.pt/euadr/ EU-ADR has contributed to the ability to conduct better drug safety studies based on the re-use of healthcare data. By facilitating the early detection of adverse drug reactions, but also providing key information on populations at risk, potential drug interactions, potential underlying mechanisms and intervening pathways in adverse events, etc., the project will allow for improved and more complete information to be available for drug and healthcare delivery, leading to increased patient safety and its associated cost savings. The EU-ADR system can be considered as a complementary tool to already existing pharamcovigilance systems. Should the system be widespread in the long term, it has the potential to contribute to the development of future electronic health record systems, insofar as the expected benefits of these IT tools are only fully attainable when EHRs develop themselves in consistency, richness and formats that allow them to be subject of such tools. In anticipation, EU-ADR has been designed to be modular and scalable, so that different EHR databases (other than those participating in the Consortium) can be progressively enlisted in the future, adopt the software for data extraction and therefore become susceptible of exploitation by the system, for maximum global effect. | adverse drug reaction, clinical, biomedical, drug safety, electronic health record, demographic, drug use, clinical data, late adult human, child, young human, pregnant, drug, adverse event, signal detection, drug development, data sharing, text mining, epidemiology, database, data set, data repository, text extraction software |
is listed by: Consortia-pedia is related to: Mar Institute of Medical Research Foundation is related to: University of Aveiro; Aveiro; Portugal has parent organization: Mar Institute of Medical Research Foundation has parent organization: University of Aveiro; Aveiro; Portugal |
European Union FP7 | nlx_158456 | SCR_004028 | Exploring and Understanding Adverse Drug Reactions by Integrative Mining of Clinical Records and Biomedical Knowledge | 2026-09-03 04:46:53 | 9 | |||||||
|
Hoosier Cancer Research Network Resource Report Resource Website |
Hoosier Cancer Research Network (RRID:SCR_004026) | HCRN | nonprofit organization | An independent nonprofit cancer research organization that provides full-service clinical trial management and support, from conception and study design through project completion and publication. Established to explore and develop leading edge cancer treatments across the United States and internationally, their clinical trials, developed in collaboration with academic and community oncologists, are conducted within a member network of more than 130 clinical research sites. Their vision and mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech partners with the goal of advancing cancer research, education, and patient advocacy. There are no costs to become a member. | oncology, clinical trial, clinical | is parent organization of: Big Ten Cancer Research Consortium | Cancer | nlx_158453, Wikidata: Q30287333, grid.428706.f | https://ror.org/02mtpb511 | SCR_004026 | Hoosier Oncology Group | 2026-09-03 04:47:01 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the Neuroscience Information Framework Project, designed to serve the biomedical research community. NIF maintains the largest searchable collection of neuroscience data, the largest catalog of biomedical resources, and the largest ontology for neuroscience on the web. We welcome all feedback and suggestions and are actively looking for resource providers to make their resources accessible through NIF. Learn about the tools available to help you share your data and discover a dynamic inventory of Web-based neuroscience resources.
